NIR-labeled perfluoropolyether nanoemulsions for drug delivery and imaging

详细信息	查看全文 | 推荐本文 |

• 作者：Claire E. O’ ; Hanlon^a ; Konjit G. Amede^a ; Meredith R. O’ ; Hear^b ; Jelena M. Janjic^a ; ^{janjicj@duq.edu}
• 关键词：Theranostic ; PFPE ; NIR ; Drug delivery ; Imaging ; 19F MRI
• 刊名：Journal of Fluorine Chemistry
• 出版年：2012
• 期刊代码：52_00221139
• 类别：ch
• 出版时间：May, 2012
• 卷：137
• 期：Complete
• 页码：27-33
• 文件大小：785 K

摘要

Theranostic nanoparticle development recently took center stage in the field of drug delivery nanoreagent design. Theranostic nanoparticles combine therapeutic delivery systems (liposomes, micelles, nanoemulsions, etc.) with imaging reagents (MRI, optical, PET, CT). This combination allows for non-invasive in vivo monitoring of therapeutic nanoparticles in diseased organs and tissues. Here, we report a novel perfluoropolyether (PFPE) nanoemulsion with a water-insoluble lipophilic drug. The formulation enables non-invasive monitoring of nanoemulsion biodistribution using two imaging modalities, ¹⁹F MRI and near-infrared (NIR) optical imaging. The nanoemulsion is composed of PFPE-tyramide as a ¹⁹F MRI tracer, hydrocarbon oil, surfactants, and a NIR dye. Preparation utilizes a combination of self-assembly and high energy emulsification methods, resulting in droplets with average diameter 180 nm and low polydispersity index (PDI less than 0.2). A model nonsteroidal anti-inflammatory drug (NSAID), celecoxib, was incorporated into the formulation at 0.2 mg/mL. The reported nanoemulsion's properties, including small particle size, visibility under ¹⁹F NMR and NIR fluorescence spectroscopy, and the ability to carry drugs make it an attractive potential theranostic agent for cancer imaging and treatment.